he3286
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00555451)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 17-ethynyl-5-androstene-3, 7, 17-triol
- 17-ethynyl-5-androstene-3,7,17-triol
- he3286
- he3286
- he3286
- he3286
- he-3286
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00991107 | Phase 1 | Sep 1, 2009 | Harbor Therapeutics |
| NCT00712114 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | Harbor Therapeutics |
| NCT00694057 | Phase 2 | Jun 1, 2008 | Harbor Therapeutics |
| NCT00628433 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2008 | Harbor Therapeutics |
| NCT00555451 | Phase 1 | Oct 1, 2007 | Harbor Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harbor Therapeutics | For profit | 5 | 5 | 2 | 2007 |
1 organizations
Page 1 / 1